<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144378</url>
  </required_header>
  <id_info>
    <org_study_id>irinotecan vs. bsc</org_study_id>
    <nct_id>NCT00144378</nct_id>
  </id_info>
  <brief_title>Irinotecan Versus Only Best Supportive Care for Gastric Cancer</brief_title>
  <official_title>Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      The median survival at progression after first-line chemotherapy for metastatic gastric&#xD;
      cancer is about 2.5 months. There are no data which a possible benefit of second line&#xD;
      therapy. for this reason a trial which investigates a possible benefit or chemotherapy&#xD;
      compared to best supportive care as second line treatment is urgently necessary.&#xD;
&#xD;
      Irinotecan shows response rates of 20% in the first line therapy with high rates od disease&#xD;
      stabilization. There are few trials investigating irinotecan in the second line setting.&#xD;
      Response rates of 20% are reported in tis setting. Irinotecan is supplied without costs from&#xD;
      the company Pfizer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic gastric cancer, progressive disease after one palliative chemotherapy&#xD;
&#xD;
      Arm A:&#xD;
&#xD;
      Irinotecan 250/350 mg/m2 q3w&#xD;
&#xD;
        1. Cycle:250mg/m2/ 30min&#xD;
&#xD;
        2. Cycle:If no toxicity&gt;2° CTC, nor Leuko-thrombopenia&gt;3° occured, dose is increased to&#xD;
           350mg/m2 Arm B. Best supportive care&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life, response rates, time to tumor progression, toxicity</measure>
  </secondary_outcome>
  <enrollment>44</enrollment>
  <condition>Stomach Neoplasm</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with histologically proven adenocarcinoma of stomach or the gastro-esophageal&#xD;
             junction&#xD;
&#xD;
          -  Patient with distant metastases laparoscopically proven operative incurability of an&#xD;
             locally advanced gastric cancer or patient with a tumor recurrence after gastrectomy&#xD;
&#xD;
          -  Patient with progressive disease under a palliative first-line chemotherapy or&#xD;
             progressive disease within 6 months after termination of a first-line chemotherapy,&#xD;
             defined as objective progression by imaging techniques according to WHO criteria&#xD;
&#xD;
          -  Age 18 and 75 years&#xD;
&#xD;
          -  Sufficient liver function, defined as serum-bilirubin &lt;1,5 mg/dl (1,5 upper normal&#xD;
             limit), ALT und AST &lt; 3x upper normal limit&#xD;
&#xD;
          -  Sufficient renal function, defined as serum creatinine &lt; 1,25 x upper normal limit or&#xD;
             creatinine clearance &gt;60ml/min calculated according to Crockroft-Gault&#xD;
&#xD;
          -  Contraction for patient with reproductive potential&#xD;
&#xD;
          -  Karnofsky-Index &gt;60%&#xD;
&#xD;
          -  Measurable or evaluable tumor manifestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor progression later than 6 months after termination of first-line chemotherapy&#xD;
&#xD;
          -  KI 50% or less&#xD;
&#xD;
          -  Patient who have already received a second line chemotherapy for the metastatic&#xD;
             setting (adjuvant chemotherapy and one line of palliative chemotherapy os allowed,&#xD;
             biologic prior therapies are allowed)&#xD;
&#xD;
          -  Prior or current second malignancy despite of basal carcinoma of the skin and&#xD;
             curatively treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  CNS metastases&#xD;
&#xD;
          -  Other severe medical illness&#xD;
&#xD;
          -  Prior major surgery less than 2 weeks ago&#xD;
&#xD;
          -  Parallel treatment with another experimental therapy&#xD;
&#xD;
          -  Parallel treatment with another therapy aiming at tumor reduction&#xD;
&#xD;
          -  Chronic diarrhea, subileus&#xD;
&#xD;
          -  Chronic inflammatory bowel disease or intestinal obstruction&#xD;
&#xD;
          -  Pretreatment with irinotecan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P Reichardt MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité, University,Campus Virchow Klinikum, Dep. of Hematology and Oncology,Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PC Thuss-Patience MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité, University,Campus Virchow Klinikum,Dep. of Hematology and Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité,Universitätsmedizin Berlin, Campus Virchow Klinikum, Dep. orf Hematology and Oncology,</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>April 17, 2007</last_update_submitted>
  <last_update_submitted_qc>April 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2007</last_update_posted>
  <keyword>gastric cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

